Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $100 to $118.
Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $100 to $118.